市场调查报告书
商品编码
1470917
横向流动化验的全球市场:按产品类型、技术、测试类型、应用和最终用户 - 预测 2024-2030Lateral Flow Assays Market by Product (Kits & Reagents, Lateral Flow Readers), Technique (Competitive Assays, Multiplex Detection Assays, Sandwich Assays), Test Type, Application, End-User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年全球横向流动化验市场规模为96.5亿美元,2024年达到100.3亿美元,预计2030年将达到129.6亿美元,复合年增长率为4.30%。
横向流动化验(LFA) 是一种快速诊断测试,用于检测复杂混合物中是否存在目标分析物。由于其成本效益、易用性和快速结果,这些检测方法被广泛应用于各个领域,包括医疗诊断、环境监测和食品安全中的就地检验和家庭检测。 LFA 利用毛细管作用将样本抽取到含有特定抗体或抗原的试纸上,通常在几分钟内提供视觉上可观察到的讯号。包括 COVID-19、流感和 HIV 在内的全球感染疾病负担日益加重,更需要 LFA 等快速且易于使用的诊断工具,以促进早期检测和管理。医疗保健的分散化以及对即时检测便利性的日益增长的需求正在支持 LFA 在各种医疗保健环境中的采用。然而,更灵敏和定量技术的存在对 LFA 构成了竞争威胁,特别是在高灵敏度很重要的应用中。此外,LAF 的技术局限性,例如灵敏度和特异性降低,以及由于交叉反应或不当使用而可能出现假阳性/阴性的可能性,引发了对其准确性和可靠性的担忧。然而,主要相关人员正在探索数位和定量 LAF 的开发及其与智慧型手机技术的集成,以进行资料分析和共用,以克服性能问题并提高 LAF 的准确性和效率。材料科学和生物技术的进步有可能提高 LFA 的敏感度、特异性和多重功能,从而扩大其在各个领域的效用和采用。
主要市场统计 | |
---|---|
基准年[2023] | 96.5亿美元 |
预测年份 [2024] | 100.3亿美元 |
预测年份 [2030] | 129.6亿美元 |
复合年增长率(%) | 4.30% |
改进产品套件和试剂的功能、性能和适用性的新进展
LFA中包含的套件和试剂在医疗保健、食品和饮料、环境监测和农业等领域中发挥着至关重要的作用。这些组件预製在硝化纤维膜上,并装在塑胶外壳内。为了检验测定性能,将发生反应的一条或多条测试线与控制线整合在一起。试剂包括对目标分析物特异性的抗体或抗原,并与胶体金或其他颗粒缀合以表达讯号。套件提供检测所需的所有组件,并确保易用性和可靠性,这使得它们对于就地检验、现场测试和品管流程至关重要。侧向流读取仪是先进的仪器,旨在以高精度和可靠性定量或定性解释 LFA 结果。与传统的目视检查方法不同,这些阅读器利用先进的光学系统来准确检测和测量测试和控制线。量化测试线的强度大大提高了检测的灵敏度和特异性,并提供客观的分析。侧向流读取仪适合实验室和现场使用,提供资料管理和可追溯性的连接选项,这对于临床诊断、食品安全通讯协定和环境监测至关重要。桌上型侧向流读取仪是一款专为实验室使用而设计的先进仪器,透过量化世界横向流动化验测试线的强度来提供高度准确的结果。这些仪器通常用于临床诊断、研究和开发以及品管过程,与多种检测格式相容。桌上型读码器可提供准确且可重复的结果,通常可以与实验室资讯管理系统 (LIMS) 集成,以储存资料并简化工作流程和资料分析。数位或手持式侧向流读取仪为现场诊断测试提供了可携式解决方案,非常适合现场使用、照护现场设置以及无法访问完整测试设施的偏远地区。这些紧凑的设备透过解释世界范围内的横向流动化验中的测试和控制线来提供快速、定性和定量分析。行动或智慧型手机阅读器是横向流动化验技术的创新飞跃,利用智慧型手机的普遍性和先进功能来执行和解释测试。这些读取器利用智慧型手机的摄影机和运算能力,结合专用的应用程式和软体来分析试纸。这种方法将使诊断测试民主化,并提高其对广大用户的可近性和便利性。
应用临床测试需要快速、准确且易于使用的解决方案
横向流动化验(LFA) 在临床检测中发挥着至关重要的作用,可提供快速、经济高效且使用者友好的诊断解决方案。 LFA 广泛用于检测感染疾病、怀孕和药物滥用,并促进即时检测,无需复杂的设备或训练有素的人员。奈米技术与先进生物辨识元件的融合,进一步提高了LFA的敏感度和特异性,使其成为临床诊断不可或缺的一部分。在药物开发和品质检测领域,LFA 是快速筛检、生物有效性和生物等效性测试的宝贵工具。 LFA 在药物试验的药物动力学分析中发挥关键作用,为安全性和有效性评估提供及时的资料。此外,LFA 用于检测污染物并确保药品质量,从而保护公众健康并保持法规遵循。 LFA技术在食品安全和环境检测中的应用是检测病原体、毒素、农药和其他有害物质的快速实用的方法。 LFA 易于使用且减少了样品製备的需要,使其成为现场测试的一个有吸引力的选择,以确保食品安全和品质并监测环境污染物。多重检测的发展使得同时检测多个目标成为可能,为公共卫生和安全做出了重大贡献。 LFA广泛应用于兽医诊断,为各种动物疾病的检测提供快速结果。其简单性、成本效益高、对技术设备和环境要求低,特别适合在野外和资源有限的环境中使用。无论是家庭宠物、家养动物或野生动物,LFA 都有助于疾病的早期发现和管理,有助于动物健康并预防潜在的人畜共通感染疾病。
区域洞察
以美国和加拿大为中心的美洲地区是横向流动化验领域高度先进的市场,拥有高额医疗保健支出、先进的医疗保健基础设施以及对研发的高度重视。感染疾病的快速诊断测试和药物测试是值得注意的应用。最近的专利强调了检测灵敏度和特异性方面的进步。许多新兴企业和老牌公司正在投资开发新应用并扩大其产品范围。在强而有力的法律规范和医疗基础设施的支持下,欧盟国家横向流动化验的全球采用率很高。该地区的着名研究和专利主要集中在资料分析和与行动装置整合的复用功能。欧盟层级的倡议旨在提高诊断测试的负担能力和取得机会,特别是在服务不足的地区。在旨在改善医疗保健和对抗感染疾病的政府倡议的推动下,亚太地区是横向流动化验领域快速增长的地区。重点放在本地生产和研究上,以减少对进口商品的依赖。日本市场的特点是技术创新水准高,消费者愿意采用先进的诊断方法。人口老化进一步增加了慢性病管理中快速检测的需求。由于人们对就地检验及其在管理感染疾病和慢性病方面的好处的认识不断增强,印度的需求正在迅速增长。最近的倡议旨在加强当地製造能力和分销网络,以改善全国范围内获得诊断测试的机会。
FPNV定位矩阵
FPNV定位矩阵对于评估全球横向流动化验市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对全球横向流动化验市场中供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争评估与资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1. 全球横向流动化验市场的市场规模与预测为何?
2.在全球横向流动化验市场的预测期间内,有哪些产品、细分市场、应用和领域需要考虑投资?
3. 全球横向流动化验市场的技术趋势和法规结构是什么?
4.全球横向流动化验市场主要厂商的市场占有率为何?
5. 进入全球横向流动化验市场的适当型态和策略手段是什么?
[193 Pages Report] The Lateral Flow Assays Market size was estimated at USD 9.65 billion in 2023 and expected to reach USD 10.03 billion in 2024, at a CAGR 4.30% to reach USD 12.96 billion by 2030.
Lateral flow assays (LFAs) are rapid diagnostic tests used for detecting the presence or absence of a target analyte in complex mixtures. These assays are widely utilized in medical diagnostics for point-of-care testing and home testing and in various fields such as environmental monitoring and food safety due to their cost-effectiveness, ease of use, and rapid results. LFAs rely on the principle of capillary action to draw a sample across a test strip that contains specific antibodies or antigens, leading to a visually observable signal, typically within minutes. The growing global burden of infectious diseases, including COVID-19, influenza, and HIV, drives the need for rapid, easy-to-use diagnostic tools like LFAs, facilitating early detection and management. The growing need for decentralized healthcare and the convenience of point-of-care testing supports the increased adoption of LFAs across various healthcare settings. However, the presence of more sensitive and quantitative technologies poses a competitive threat to LFAs, especially in applications where high sensitivity is crucial. Furthermore, technical limitations of the LAFs, such as reduced sensitivity and specificity and the potential for false positives/negatives due to cross-reactivity or improper use, can raise concerns about their accuracy and reliability. However, key players are exploring the development of digital and quantitative LFAs and integration with smartphone technology for data analysis and sharing to overcome performance issues and improve LAFs' accuracy and efficiency. Advances in materials science and biotechnology hold the potential to enhance the sensitivity, specificity, and multiplexing capabilities of LFAs, thereby broadening their utility and adoption in various sectors.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 9.65 billion |
Estimated Year [2024] | USD 10.03 billion |
Forecast Year [2030] | USD 12.96 billion |
CAGR (%) | 4.30% |
Product: Emerging advancements to improve the functionality, performance, and applicability of kits and reagents
The kits and reagents involved in LFAs play a pivotal role in the healthcare, food and beverage, environmental monitoring, and agricultural sectors, among others. These components come prefabricated on a nitrocellulose membrane and housed within a plastic casing. They integrate one or multiple test lines where reactions occur alongside control lines to validate the assay's performance. The reagents include antibodies or antigens specific to the analyte of interest, conjugated with colloidal gold or other particles for signal development. The kits provide all necessary components for the assay, ensuring ease of use and reliability, making them essential for point-of-care testing, field testing, and quality control processes. Lateral flow readers are sophisticated devices designed to quantitatively or qualitatively interpret the results of LFA with high precision and reliability. Unlike the traditional visual inspection method, these readers utilize advanced optical systems to accurately detect and measure the test and control lines. They significantly enhance the assay's sensitivity and specificity by quantifying the intensity of the test line, thus providing an objective analysis. Suitable for both laboratory and field use, lateral flow readers offer connectivity options for data management and traceability, which is pivotal for clinical diagnostics, food safety protocols, and environmental monitoring. Benchtop lateral flow readers are sophisticated instruments designed for laboratory use, providing high-accuracy results by quantifying the test line's intensity on lateral flow assays. These devices, often employed in clinical diagnostics, research and development laboratories, and quality control processes, support a wide range of assay formats. Benchtop readers deliver precise, reproducible results and can often store data and integrate with laboratory information management systems (LIMS) to streamline workflow and data analysis. Digital or handheld lateral flow readers offer a portable solution for on-the-spot diagnostic testing, making them ideal for field use, point-of-care settings, and remote locations where access to full laboratory facilities is limited. These compact devices provide rapid, qualitative, and quantitative analyses by interpreting the test and control lines on lateral flow assays. Mobile or smartphone readers represent an innovative leap in lateral flow assay technology, leveraging the ubiquity and advanced capabilities of smartphones to perform and interpret tests. These readers utilize a smartphone's camera and computational power, coupled with specialized apps or software, to analyze test strips. This approach democratizes diagnostic testing, enhancing accessibility and convenience for a wide user base.
Application: Need for rapid, accurate, and accessible solutions in clinical testing
Lateral flow assays (LFA) hold a pivotal role in clinical testing, offering rapid, cost-effective, and user-friendly diagnostic solutions. They are widely utilized for the detection of infectious diseases, pregnancy, and drug abuse testing and facilitate point-of-care testing without the need for sophisticated equipment or highly trained personnel. The integration of nanotechnologies and advanced biorecognition elements has further enhanced their sensitivity and specificity, making LFAs indispensable in clinical diagnostics. In the realm of drug development and quality testing, LFAs offer valuable tools for rapid screening, bioavailability, and bioequivalence studies. They serve crucially in the pharmacokinetic analysis of drug trials, providing timely data that is essential for safety and efficacy assessments. Additionally, LFAs are employed to detect contaminants and ensure the quality of pharmaceutical products, thereby safeguarding public health and maintaining regulatory compliance. The application of LFA technology in food safety and environmental testing represents a fast and practical approach to detecting pathogens, toxins, pesticides, and other harmful agents. Its ease of use and the minimal requirement for sample preparation make LFA an attractive option for on-site testing, ensuring the safety and quality of food products and monitoring environmental pollutants. The development of multiplexed assays has enabled the simultaneous detection of multiple targets, significantly benefitting public health and safety. LFAs are extensively applied in veterinary diagnostics, providing rapid results for the detection of various animal diseases. Their simplicity, cost-effectiveness, and the minimal need for technical equipment or environments make them especially suited for use in field conditions or in resource-limited settings. Whether for domestic pets, livestock, or wildlife, LFAs help in the early detection and management of diseases, contributing to animal health and preventing potential zoonotic transmissions to humans.
Regional Insights
The Americas region, particularly the U.S. and Canada, represents a highly advanced market for lateral flow assays, driven by high healthcare expenditure, advanced healthcare infrastructure, and a strong focus on research and development. Rapid diagnostic testing for infectious diseases and drug testing are prominent applications. Recent patents emphasize advancements in the sensitivity and specificity of assays. Numerous startups and established companies are investing in the development of new applications and the expansion of product range. EU countries show a high adoption rate for lateral flow assays, favored by a strong regulatory framework and healthcare infrastructure. Notable research and patents in the region focus on multiplexing capabilities and integration with mobile devices for data analysis. Initiatives at the EU level aim to improve affordability and access to diagnostic testing, particularly in underserved areas. APAC is a rapidly growing region for lateral flow assays, driven by government initiatives aimed at improving healthcare access and combating infectious diseases. There is a significant focus on local production and research to reduce dependency on imports. Japan's market is characterized by high innovation and consumer willingness to adopt advanced diagnostic methods. Aging population dynamics further fuel the need for rapid testing in chronic disease management. The demand in India is rapidly increasing due to rising awareness about point-of-care testing and its benefits in managing infectious diseases and chronic conditions. Recent initiatives aim to enhance local manufacturing capabilities and distribution networks to improve access to diagnostic tests across the country.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Lateral Flow Assays Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Lateral Flow Assays Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Lateral Flow Assays Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Inc., Abcam PLC, BBI Solutions, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corp., BioFluidix GmbH by Hamilton Company, BioMerieux SA, BioPorto Diagnostics A/S, BOC Sciences, Cytodiagnostics Inc., Danaher Corporation, Elabscience Biotechnology Inc., F. Hoffmann-La Roche AG, Fortis Life Sciences, Hologic, Inc., Leinco Technologies, Merck KGaA, Microcoat Biotechnologie GmbH, Milenia Biotec GmbH, PerkinElmer Inc., Porex Filtration Group, QIAGEN GmbH, Quidel Corporation, R-Biopharm AG, Rockland Immunochemicals, Inc., Shenzhen SEKBIO Co., Ltd., Siemens AG, Tetracore, Inc., Thermo Fisher Scientific, Inc., and VDO Biotech Co., Ltd..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Lateral Flow Assays Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Lateral Flow Assays Market?
3. What are the technology trends and regulatory frameworks in the Lateral Flow Assays Market?
4. What is the market share of the leading vendors in the Lateral Flow Assays Market?
5. Which modes and strategic moves are suitable for entering the Lateral Flow Assays Market?